Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, announced that it has renewed its previously established at-the-market equity program. The “ATM Program” allows Cybin to issue and sell up to US$35,000,000 of common shares in the capital of the … Continue reading InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Renewed ATM Program of up to US$35M